Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Aug. 31, 2018
Aug. 31, 2017
Cash flows from operating activities:    
Net (loss) income $ (1,745,582) $ 1,635,882
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization expense 214,275 171,689
Loss on disposal of property and equipment 153,756  
Compensatory element of stock options 323,798 709,173
Provision for doubtful accounts 539,365 (2,876)
Deferred income tax expense 3,117,263 73,512
Amortization of debt issuance costs 79,876 96,869
Changes in assets and liabilities:    
Accounts receivable (805,183) (805,398)
Prepaid expenses (156,022) (10,560)
Inventory 182,466 25,385
Other current assets (3,066) (104,669)
Deposits and other assets, net   (3,388)
Accounts payable (808,839) (122,237)
Accrued expenses (99,555) (727,969)
Deferred revenue 3,496,790 2,671,172
Net cash provided by operating activities 4,489,342 3,606,585
Cash flows from investing activities:    
Purchases of property and equipment (408,297) (55,182)
Purchase of intangible asset (200,000)  
(Purchases) sales of marketable securities and other investments, net (105,186) 161,023
Net cash (used in) provided by investing activities (11,213,483) 105,841
Cash flows from financing activities:    
Treasury stock purchases   (446,621)
Repayments of note payable (1,516,666) (2,149,999)
Proceeds from the exercise of stock options 170,925 51,396
Proceeds from note payable 9,000,000  
Issuance costs associated with the proceeds from the note payable (169,300)  
Net cash provided by (used in) financing activities 7,484,959 (2,545,224)
Increase in cash and cash equivalents 760,818 1,167,202
Cash and cash equivalents - beginning of period 6,279,154 3,499,881
Cash and cash equivalents - end of period 7,039,972 4,667,083
Supplemental non-cashinvesting activities:    
Unrealized gain on marketable securities, net of tax 405,255 $ 60,678
Assets acquired and liabilities assumed in acquisitions:    
Assets acquired in acquisition 20,103,661  
Liabilities assumed in acquisition 1,405,406  
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member]    
Cash flows from investing activities:    
Purchase of Cord Use $ (10,500,000)